Nanexa AB (publ) (FRA:40M)

Market Cap	27.11M
Revenue (ttm)	2.89M
Net Income (ttm)	-3.53M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	208
Average Volume	10
Open	0.1418
Previous Close	0.1328
Day's Range	0.1418 - 0.1418
52-Week Range	0.0690 - 0.2410
Beta	n/a
RSI	52.61
Earnings Date	Feb 19, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2007
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 40M

Financial Performance

In 2024, Nanexa AB's revenue was 46.69 million, a decrease of -21.07% compared to the previous year's 59.16 million. Losses were -24.91 million, -67.40% less than in 2023.

Financial numbers in SEK